BridgeMD
New treatment option for COVID-19
Official title Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19
ClinicalTrials.gov ID: NCT06703034
What this study is testing
- What it's testing
- Type I interferon (IFN-I) production is triggered by the detection of viral molecules, such as strands of viral RNA or DNA, by receptors known as PRRs (Pattern Recognition Receptors) present on many cell types. These interferons are secreted in minimal concentrations but can activate neighboring cells to secrete over 700 proteins with antiviral properties (inhibition of viral replication, destabilization of viral membranes, etc.).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participant aged at least 18 years
- Previously included in the COVID-ser or NOSO-COR IMMUNO study as well as in the RNIPH study (Research Not Involving Human Persons) named MIR-COVID
- Weight of 50 kg or more
You likely can't join if
- Current infection symptoms
- Immunosuppression defined by: bone marrow transplant within the past 24 months, chemotherapy within the past 6 months, HIV infection with CD4...
- Pregnant, parturient, or breastfeeding woman
- Person deprived of liberty by judicial or administrative decision
- Person receiving psychiatric care
- Person admitted to a health or social institution for purposes other than research
See the full eligibility criteria
- Participant aged at least 18 years
- Previously included in the COVID-ser or NOSO-COR IMMUNO study as well as in the RNIPH study (Research Not Involving Human Persons) named MIR-COVID
- Weight of 50 kg or more
- Current infection symptoms
- Immunosuppression defined by: bone marrow transplant within the past 24 months, chemotherapy within the past 6 months, HIV infection with CD4 \<200/mm³ or \<15%, corticosteroid therapy for more than 2 weeks with a daily...
- Pregnant, parturient, or breastfeeding woman
- Person deprived of liberty by judicial or administrative decision
- Person receiving psychiatric care
- Person admitted to a health or social institution for purposes other than research
- Person under guardianship or curators
- Person not affiliated with a social security scheme or similar coverage
- Patient participating in another ongoing treatment research study at inclusion"
The study team makes the final eligibility decision.
Where it's taking place
- Lyon, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lyon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.